Eyenuk
AI eye screening
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- MedTech
- Warner Center, Los Angeles, CA
Jump to section
Company mission
To screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
Our take
More than 400 million people globally are living with diabetes. Aside for being responsible for 1.5 Million deaths a year, the disease also predisposes its sufferers to a form of blindness called diabetic retinopathy, a condition which can develop silently and which often goes undetected. Eyenuk is utilising clinical AI to detect this and other potentially blinding diseases at large scale so they can be treated and prevented before they ruin lives.
Eyenuk's technology provides automated retinopathy screening without the need for expert inspection or the eye dilation which is usually required, allowing clinics to conduct all stages of a screening in a single visit and letting them refer patients to eye care specialists immediately. The system uses AI and a vast library of images to detect irregularities which might be difficult to spot with the human eye. Already in use with the NHS and US private and public medical systems, and cleared for use within the EU, Eyenuk has screened tens of thousands of patients globally since 2020.
Having raised a significant amount of funding, most recently in a 2022 Series A round, Eyenuk aims to expand its platform, adding more disease indications to its diagnostic systems. It also plans to scale its operations as new opportunities open up with its regulatory approval in the European Union.
Steph
Company Specialist at Welcome to the Jungle
Benefits
- Join a diverse multi-disciplinary team
- Healthy stock options in a growing company. High upside potential
- Work with an experienced team with skills in computer vision and machine learning concepts
- Work in a dynamic startup environment
- Contribute to and participate in the company growth. Own ideas, turn them into products/features, watch customers love them, and get credit for all of this
- Experience and learn how to overcome the challenges of delivering a transformative technology to the healthcare space
Funding (last 2 of 7 rounds)
Oct 2022
$26m
SERIES A
Jul 2021
$6.2m
EARLY VC
Total funding: $40.1m
Leadership
Kaushal Solanki
(CEO)Before founding Eyenuk was a Research Staff Memeber in Image Processing for Mayachitra and a Research & Teaching Assistance at University of California Santa Barbara.